Demant A/S

Latest Results (15.11.2025):

Demant A/S reported its Q3 2025 results with organic revenue growth of 3%, driven mainly by solid performance in the Hearing Care segment, despite challenges in the global hearing aid market and a sequential slowdown in the US commercial market. The report details performance variances across segments, emphasizes cost management amid shifting product mixes, and outlines a cautious full‐year 2025 outlook with EBIT toward the lower end of the anticipated range.

Organic Revenue Growth

In Q3 2025, Demant A/S achieved 3% organic growth overall. Notably, Hearing Aids generated 2% organic revenue growth externally while Hearing Care led with a 4% increase in its segment. Additional growth of 2% stemmed from acquisitions in the Hearing Care area.

Segment Performance

While Hearing Aids delivered unit market share gains, the US commercial market experienced a sequential slowdown impacting average selling prices. Hearing Care, despite a generally soft market, delivered consistent growth, and Diagnostics faced a slight decline due to weak spending in key markets.

Margin and Cost Management

The report highlights that gross margins declined, influenced by changes in product mix, negative average selling price trends, and foreign exchange effects. Operating expenses grew modestly on an organic basis, and the EBIT for Q3 2025 came in at the lower end of expectations amid these headwinds.

Outlook & Strategic Initiatives

For the remainder of 2025, Demant A/S expects organic growth to be in the 1-3% range and EBIT to fall between DKK 3,900-4,300 million. The company is actively engaging in acquisitions—most notably the pending KIND Group acquisition—and has suspended its share buy-back program, underscoring its cautious stance on market uncertainties and cost management strategies.